Bosentan: new indication. Also too risky in mildly symptomatic pulmonary arterial hypertension. No proven tangible benefit in mildly symptomatic patients, and too many adverse effects.

摘要

Bosentan (Tracleer, Actelion) has been marketed for several years for patients with functional class III pulmonary arterial hypertension. It was then licensed for functional class II patients, soon after ambrisentan was approved in this indication (see page 54) (1).